3SBio Future Growth
Future criteria checks 2/6
3SBio is forecast to grow earnings and revenue by 12.6% and 7.6% per annum respectively. EPS is expected to grow by 12% per annum. Return on equity is forecast to be 12.3% in 3 years.
Key information
12.6%
Earnings growth rate
12.0%
EPS growth rate
Biotechs earnings growth | 35.5% |
Revenue growth rate | 7.6% |
Future return on equity | 12.3% |
Analyst coverage | Good |
Last updated | 16 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 10,285 | 2,300 | 2,069 | N/A | 7 |
12/31/2025 | 9,445 | 2,133 | 1,901 | N/A | 9 |
12/31/2024 | 8,649 | 1,934 | 1,376 | N/A | 9 |
12/31/2023 | 7,816 | 1,549 | N/A | N/A | N/A |
9/30/2023 | 7,681 | 1,733 | N/A | N/A | N/A |
6/30/2023 | 7,549 | 1,929 | 1,311 | 2,337 | N/A |
3/31/2023 | 7,204 | 1,922 | 1,259 | 2,259 | N/A |
12/31/2022 | 6,859 | 1,915 | 1,207 | 2,180 | N/A |
9/30/2022 | 6,616 | 1,823 | 1,008 | 1,964 | N/A |
6/30/2022 | 6,369 | 1,719 | 856 | 1,794 | N/A |
3/31/2022 | 6,376 | 1,685 | 663 | 1,686 | N/A |
12/31/2021 | 6,382 | 1,651 | 469 | 1,578 | N/A |
9/30/2021 | 6,191 | 1,342 | 394 | 1,513 | N/A |
6/30/2021 | 6,000 | 1,032 | 318 | 1,448 | N/A |
3/31/2021 | 5,794 | 934 | 340 | 1,396 | N/A |
12/31/2020 | 5,588 | 836 | 363 | 1,345 | N/A |
9/30/2020 | 5,479 | 1,095 | 813 | 1,620 | N/A |
6/30/2020 | 5,370 | 1,355 | 1,263 | 1,896 | N/A |
3/31/2020 | 5,344 | 1,164 | 1,332 | 1,892 | N/A |
12/31/2019 | 5,318 | 974 | 1,401 | 1,887 | N/A |
9/30/2019 | 5,185 | 1,029 | 1,257 | 1,645 | N/A |
6/30/2019 | 5,053 | 1,084 | 1,113 | 1,403 | N/A |
3/31/2019 | 4,818 | 1,181 | 915 | 1,277 | N/A |
12/31/2018 | 4,584 | 1,277 | 717 | 1,150 | N/A |
9/30/2018 | 4,393 | 1,167 | 695 | 1,160 | N/A |
6/30/2018 | 4,202 | 1,057 | 673 | 1,171 | N/A |
3/31/2018 | 3,968 | 996 | 752 | 1,122 | N/A |
12/31/2017 | 3,734 | 935 | 831 | 1,074 | N/A |
9/30/2017 | 3,467 | 877 | N/A | 1,017 | N/A |
6/30/2017 | 3,199 | 818 | N/A | 960 | N/A |
3/31/2017 | 2,998 | 766 | N/A | 982 | N/A |
12/31/2016 | 2,797 | 713 | N/A | 1,004 | N/A |
9/30/2016 | 2,492 | 642 | N/A | 794 | N/A |
6/30/2016 | 2,188 | 571 | N/A | 583 | N/A |
3/31/2016 | 1,930 | 548 | N/A | 519 | N/A |
12/31/2015 | 1,673 | 526 | N/A | 455 | N/A |
9/30/2015 | 1,503 | 456 | N/A | 521 | N/A |
6/30/2015 | 1,364 | 341 | N/A | 534 | N/A |
3/31/2015 | 1,247 | 316 | N/A | 460 | N/A |
12/31/2014 | 1,131 | 292 | N/A | 387 | N/A |
9/30/2014 | 1,044 | 238 | N/A | 301 | N/A |
12/31/2013 | 875 | 96 | N/A | 217 | N/A |
9/30/2013 | 842 | 95 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1530's forecast earnings growth (12.6% per year) is above the savings rate (2%).
Earnings vs Market: 1530's earnings (12.6% per year) are forecast to grow faster than the Hong Kong market (11.4% per year).
High Growth Earnings: 1530's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1530's revenue (7.6% per year) is forecast to grow slower than the Hong Kong market (7.7% per year).
High Growth Revenue: 1530's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1530's Return on Equity is forecast to be low in 3 years time (12.3%).